The adhesive interactions of cells with their environment through the integrin family of
transmembrane receptors have key roles in regulating multiple aspects of cellular …

Vedolizumab is a novel therapeutic monoclonal antibody recently approved for the treatment
of moderately to severely active ulcerative colitis and Crohn's disease in adults who have …

Background & Aims The IM-UNITI study and long-term extension (LTE) evaluated the long-
term efficacy, safety, and immunogenicity of subcutaneous ustekinumab maintenance …

Background Cytotoxic T-lymphocyte antigen 4 (CTLA-4) is a negative immune regulator.
Heterozygous CTLA4 germline mutations can cause a complex immune dysregulation …

Background Gut-selective blockade of lymphocyte trafficking by vedolizumab may constitute
effective treatment for ulcerative colitis. Methods We conducted two integrated randomized …

Abstract Background and Aims: The GEMINI long-term safety [LTS] study is a continuing
phase 3 trial investigating the safety and efficacy of vedolizumab, an α4β7 integrin …

Abstract Background and Aims: Vedolizumab is a gut-selective α4β7 integrin antagonist
therapy for ulcerative colitis and Crohn's disease. The GEMINI long-term safety [LTS] trial is …

First worldwide family litigation filed litigation Critical https://patents. darts-ip. com/? family=
49447811&utm_source= google_patent&utm_medium= platform_link&utm_campaign …

First worldwide family litigation filed litigation Critical https://patents. darts-ip. com/? family=
49235350&utm_source= google_patent&utm_medium= platform_link&utm_campaign …

First worldwide family litigation filed litigation Critical https://patents. darts-ip. com/? family=
49235350&utm_source= google_patent&utm_medium= platform_link&utm_campaign …